propagermanium: Clinical Trials

3 trials of propagermanium, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Terminated 1

Follow propagermanium: new trials by email Literature Review of propagermanium trials Research Report on propagermanium

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19
Candesartan Cilexetil, Repagermanium, Candesartan Placebo - COVID-19, SARS-CoV2 Infection
Phase 2TerminatedUniversity of Sydney492022-01-072023-09-15
Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
Propagermanium, Placebo - Focal Segmental Glomerulosclerosis
Phase 2CompletedDimerix Bioscience Pty Ltd82018-11-082022-07-29
Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan
Propagermanium, Placebo - Diabetic Kidney Disease
Phase 2CompletedDimerix Bioscience Pty Ltd452018-11-062022-07-29

Conditions studied

COVID-19 (1)  ·  Diabetic Nephropathies (1)  ·  Glomerulosclerosis, Focal Segmental (1)

Sponsors

Dimerix Bioscience Pty Ltd (2)  ·  University of Sydney (1)

Countries

Australia (2)  ·  India (1)

Top investigators

Simon Roger, MD (2)  ·  Meg Jardine (1)  ·  Vivekanand Jha (1)

Results publications

PMID 35224732, PMID 39438096